Currently, transcatheter pulmonary valve replacement (TPVR) is a well-established alternative for surgical pulmonary valve replacement (SPVR) to treat pulmonary valve disorders in patients with prior congenital heart surgery. Edwards Sapien 3 valve is a bioprosthesis originally designed for the aortic position but has been used off-label in native right ventricular outflow tract (RVOT). It is currently under clinical trial to get food and drug administration (FDA) approval.
This study is a comparison of the performance of Sapien 3 with surgical bioprosthetics. The in vitro tests result showed Sapien 3 experiences less degree of opening and effective orifice area in pulmonic conditions than surgical valves. The less opening area of the leaflets is a concern after TPVR since it may initiate subclinical leaflet thrombosis and valve stenosis over time. Computational results also showed that the maximum in-plane stress value was higher in Sapien 3 than in surgical valves.
","abstract_html":"<p>Currently, transcatheter pulmonary valve replacement (TPVR) is a well-established alternative for surgical pulmonary valve replacement (SPVR) to treat pulmonary valve disorders in patients with prior congenital heart surgery. Edwards Sapien 3 valve is a bioprosthesis originally designed for the aortic position but has been used off-label in native right ventricular outflow tract (RVOT). It is currently under clinical trial to get food and drug administration (FDA) approval.</p> <p>This study is a comparison of the performance of Sapien 3 with surgical bioprosthetics. The in vitro tests result showed Sapien 3 experiences less degree of opening and effective orifice area in pulmonic conditions than surgical valves. The less opening area of the leaflets is a concern after TPVR since it may initiate subclinical leaflet thrombosis and valve stenosis over time. Computational results also showed that the maximum in-plane stress value was higher in Sapien 3 than in surgical valves.</p>","abstract_has_math":false,"creators":["Shafiei, Mina"],"institution":null,"degree_name":"M.S.","degree_level":"Masters Thesis","degree_discipline":null,"degree_department":null,"school":null,"contributors":["Ali N. Azadani","Matt J. Rutherford","Matt H. Gordon"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2022,"date_issued":"2022-01-01T08:00:00Z","date_published":"2022-01-01T08:00:00Z","updated_at":"2026-07-24T02:02:03Z","subjects":["Balloon pulmonary angioplasty (BPA)","Food and Drug Administration (FDA)","Surgical pulmonary valve replacement (SPVR)","Transcatheter pulmonary valve replacement (TPVR)","Biological Engineering","Biomechanics and Biotransport","Biomedical Engineering and Bioengineering","Engineering"],"languages":["en"],"rights":["Copyright is held by the author. User is responsible for all copyright compliance.
"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.du.edu/etd/2163","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Ali N. Azadani","Matt J. Rutherford","Matt H. Gordon"]},{"key":"dc:creator","label":"Author","values":["Shafiei, Mina"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"thesis:degree_level","label":"Degree Level","values":["Masters Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["M.S."]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Balloon pulmonary angioplasty (BPA)","Food and Drug Administration (FDA)","Surgical pulmonary valve replacement (SPVR)","Transcatheter pulmonary valve replacement (TPVR)","Biological Engineering","Biomechanics and Biotransport","Biomedical Engineering and Bioengineering","Engineering"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["Copyright is held by the author. User is responsible for all copyright compliance.
"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.du.edu/etd/2163"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Currently, transcatheter pulmonary valve replacement (TPVR) is a well-established alternative for surgical pulmonary valve replacement (SPVR) to treat pulmonary valve disorders in patients with prior congenital heart surgery. Edwards Sapien 3 valve is a bioprosthesis originally designed for the aortic position but has been used off-label in native right ventricular outflow tract (RVOT). It is currently under clinical trial to get food and drug administration (FDA) approval.
This study is a comparison of the performance of Sapien 3 with surgical bioprosthetics. The in vitro tests result showed Sapien 3 experiences less degree of opening and effective orifice area in pulmonic conditions than surgical valves. The less opening area of the leaflets is a concern after TPVR since it may initiate subclinical leaflet thrombosis and valve stenosis over time. Computational results also showed that the maximum in-plane stress value was higher in Sapien 3 than in surgical valves.
"]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Pulmonary Valve Replacement"]}]}],"canonical_facts":{"dc:contributor":["Ali N. Azadani","Matt J. Rutherford","Matt H. Gordon"],"dc:creator":["Shafiei, Mina"],"dc:description.abstract":["Currently, transcatheter pulmonary valve replacement (TPVR) is a well-established alternative for surgical pulmonary valve replacement (SPVR) to treat pulmonary valve disorders in patients with prior congenital heart surgery. Edwards Sapien 3 valve is a bioprosthesis originally designed for the aortic position but has been used off-label in native right ventricular outflow tract (RVOT). It is currently under clinical trial to get food and drug administration (FDA) approval.
This study is a comparison of the performance of Sapien 3 with surgical bioprosthetics. The in vitro tests result showed Sapien 3 experiences less degree of opening and effective orifice area in pulmonic conditions than surgical valves. The less opening area of the leaflets is a concern after TPVR since it may initiate subclinical leaflet thrombosis and valve stenosis over time. Computational results also showed that the maximum in-plane stress value was higher in Sapien 3 than in surgical valves.
"],"dc:format":["application/pdf"],"dc:identifier":["https://digitalcommons.du.edu/etd/2163"],"dc:language":["en"],"dc:rights":["Copyright is held by the author. User is responsible for all copyright compliance.
"],"dc:subject":["Balloon pulmonary angioplasty (BPA)","Food and Drug Administration (FDA)","Surgical pulmonary valve replacement (SPVR)","Transcatheter pulmonary valve replacement (TPVR)","Biological Engineering","Biomechanics and Biotransport","Biomedical Engineering and Bioengineering","Engineering"],"dc:title":["Pulmonary Valve Replacement"],"thesis:degree_level":["Masters Thesis"],"thesis:degree_name":["M.S."]},"updated_at":"2026-07-24T02:02:03Z"}